Nixon Peabody Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $762K | Buy |
2,337
+60
| +3% | +$19.6K | 0.06% | 96 |
|
|
2025
Q1 | $615K | Sell |
2,277
-16
| -0.7% | -$4.32K | 0.05% | 102 |
|
|
2024
Q4 | $540K | Buy |
2,293
+43
| +2% | +$10.1K | 0.04% | 99 |
|
|
2024
Q3 | $619K | Sell |
2,250
-1,050
| -32% | -$289K | 0.05% | 91 |
|
|
2024
Q2 | $802K | Hold |
3,300
| – | – | 0.07% | 75 |
|
|
2024
Q1 | $493K | Hold |
3,300
| – | – | 0.05% | 90 |
|
|
2023
Q4 | $632K | Buy |
3,300
+1,800
| +120% | +$345K | 0.07% | 77 |
|
|
2023
Q3 | $266K | Hold |
1,500
| – | – | 0.22% | 67 |
|
|
2023
Q2 | $285K | Hold |
1,500
| – | – | 0.23% | 66 |
|
|
2023
Q1 | $300K | Hold |
1,500
| – | – | 0.21% | 58 |
|
|
2022
Q4 | $356K | Hold |
1,500
| – | – | 0.29% | 60 |
|
|
2022
Q3 | $300K | Hold |
1,500
| – | – | 0.25% | 61 |
|
|
2022
Q2 | $219K | Hold |
1,500
| – | – | 0.1% | 66 |
|
|
2022
Q1 | $245K | Hold |
1,500
| – | – | 0.08% | 74 |
|
|
2021
Q4 | $254K | Hold |
1,500
| – | – | 0.08% | 80 |
|
|
2021
Q3 | $283K | Sell |
1,500
-500
| -25% | -$94.3K | 0.1% | 66 |
|
|
2021
Q2 | $339K | Hold |
2,000
| – | – | 0.13% | 59 |
|
|
2021
Q1 | $282K | Hold |
2,000
| – | – | 0.11% | 63 |
|
|
2020
Q4 | $260K | Hold |
2,000
| – | – | 0.11% | 65 |
|
|
2020
Q3 | $291K | Hold |
2,000
| – | – | 0.13% | 68 |
|
|
2020
Q2 | $296K | Hold |
2,000
| – | – | 0.15% | 67 |
|
|
2020
Q1 | $218K | Hold |
2,000
| – | – | 0.13% | 67 |
|
|
2019
Q4 | $230K | Buy |
+2,000
| New | +$230K | 0.11% | 74 |
|
|
2018
Q2 | – | Sell |
-2,000
| Closed | -$238K | – | 75 |
|
|
2018
Q1 | $238K | Hold |
2,000
| – | – | 0.21% | 62 |
|
|
2017
Q4 | $254K | Hold |
2,000
| – | – | 0.22% | 62 |
|
|
2017
Q3 | $235K | Buy |
+2,000
| New | +$235K | 0.21% | 64 |
|